Consistent improvement with eculizumab across muscle groups in myasthenia gravis
Thymectomy in myasthenia gravis: when, why, and how?
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial
Outcome Measures in Myasthenia Gravis: Incorporation Into Clinical Practice
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, doubleblind, placebo-controlled, multicentre study
Randomized Trial of Thymectomy in Myasthenia Gravis
Supplementary Appendix
Estudio aleatorizado de timectomía en miastenia gravi
Randomized Trial of Thymectomy in Myasthenia Gravis
Long-term effect of thymectomy in patients with nonthymomatous myasthenia gravis treated with prednisone: 2-year extension of the MGTX randomised trial
Minimal manifestation status and prednisone withdrawal in the MGTX trial
International Consensus Guidance for Management of Myasthenia Gravis
Muscle-Specific Kinase Myasthenia Gravis
AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype?
Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology
Benefit and danger from immunotherapy in myasthenia gravis
Monoclonal Antibody‑Based Therapies for Myasthenia Gravis
Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
Usted está accediendo a una sección del sitio que contiene información para profesionales de la salud.
Si usted es paciente le solicitamos dirigirse a la sección correspondiente.
